Pitfalls in RET fusion detection using break-apart FISH probes in papillary thyroid carcinoma

Author(s):  
Yuanyuan Liu ◽  
Shafei Wu ◽  
Liangrui Zhou ◽  
Yong Guo ◽  
Xuan Zeng

Abstract Objective A standardized procedure of fused REarranged during Transfection (RET) gene detection using fluorescence in situ hybridization (FISH) remains to be established in papillary thyroid carcinoma (PTC). Our purpose was to investigate false-negative and false-positive events and their FISH signal characteristics. Methods A total of 111 PTC cases were analyzed using break-apart FISH probe for RET status evaluation. All FISH results were validated using fusion-induced asymmetric transcription assay (FIATA)-based reverse transcription droplet digital PCR (RT-ddPCR). Then, suspected RET-positive cases were tested using quantitative reverse transcription-PCR (RT-qPCR) and following next-generation sequencing (NGS) for recognizing fusion variants. Results Thirty RET+ cases were revealed, including 20 CCDC6-RET (exon1;exon12), 6 NCOA4-RET (exon8;exon12), 1 NCOA4-RET (exon7;exon12), 1 CCDC186-RET (exon7;exon12), 1 ERC1-RET (exon12;exon12) and 1 SPECC1L-RET (exon9;exon12) tumors. All RET fusion cases occurred in the BRAF- population, with a prevalence of 41.7% (30/72). Four cases of 8–13% (cutoff was 7.6%) dominant isolated 3’ green (IG) FISH signals were RET-. One FISH- case with isolated 5’ red (IR) signals with 94% abnormal tumor cells was demonstrated to be positive, harboring the NCOA4-RET (exon7; exon12) variant. Compared to RET fusions characterized by dominant break-apart (BA) signals with 29–100% aberrant cells, RET + with dominant IG-signal patterns all showed more frequent FISH+ cells (84–92%). RET+ PTC with a BA signal pattern was more frequently found in unifocal lesions than in multifocal/bilateral tumors (p=0.049). Conclusions A false-positive or false-negative event may exist for RET status detection in PTCs using the traditional FISH scoring method with BA probes.

2020 ◽  
Vol 46 (6) ◽  
pp. 967-975 ◽  
Author(s):  
Ludovico M. Garau ◽  
Domenico Rubello ◽  
Simona Muccioli ◽  
Giuseppe Boni ◽  
Duccio Volterrani ◽  
...  

2018 ◽  
Vol 8 (1) ◽  
pp. 1235-1243 ◽  
Author(s):  
Hafez H Nesreen ◽  
Shalaby Z Manal ◽  
Ahmed M Mohamed

Background: Although nuclear criteria are considered to be characteristic for papillary thyroid carcinoma, some cases do raise controversy as being papillary thyroid carcinoma or non-papillary thyroid carcinoma due to unclear diagnostic nuclear features. Immunohistochemical markers can help in identifying PTC. Trophoblastic cell surface antigen 2 (TROP-2) is a novel marker that is recently applied on thyroid. The aim of this study was to evaluate TROP-2 expression and diagnostic utility in PTC compared to other thyroid nodules with follicular pattern on tissue specimens and cell block sections. Materials and Methods: This retrospective study was carried out at National Cancer Institute, Cairo University between January 2010 and January 2015. Immunohistochemical evaluation of TROP-2 was applied on archival 110 surgically excised and 66 cytological cell blocks of PTC and other follicular thyroid nodules. Membranous staining, with or without cytoplasm, was considered positive.Results: Among excised specimens, 85.1% of PTC demonstrated TROP-2 staining. The majority revealed diffuse staining. No significant staining difference was reported between studied classic and non classic variants. TROP-2 sensitivity and were 85.1% and 94.4%. Among cytological materials, all PTC were positive except two (false negative) and only two follicular adenomas were positive (false positive). TROP-2 sensitivity and specificity were 93.8% and 94.1%. None of nodular hyperplasia or adjacent normal thyroid tissues showed TROP-2 immunoreactivity either on histopathological or cytological sections.Conclusion: TROP-2 positivity was significantly higher in PTC compared to all other studied non PTC lesion in both surgical pathology specimens and cytological materials. No reported significant staining difference among studied PTC variant.


2017 ◽  
Vol 42 (6) ◽  
pp. 1153-1160 ◽  
Author(s):  
K.-I. Yi ◽  
S. Ahn ◽  
D.Y. Park ◽  
J.-C. Lee ◽  
B.-J. Lee ◽  
...  

2019 ◽  
Vol 180 (1) ◽  
pp. 21-29 ◽  
Author(s):  
Carmela Iglesias Felip ◽  
Carles Zafon Llopis ◽  
Jordi Temprana-Salvador ◽  
Amparo García-Burillo ◽  
Xavier Serres Créixams ◽  
...  

Objective Lymphadenectomy in papillary thyroid carcinoma (PTC) is controversial. It is indicated whenever metastases have been proven before or during surgery and as a prophylactic treatment in high-risk patients. However, 30–50% of cN0 patients become pN1 postoperatively. In PTC, selective-sentinel-lymph-node-biopsy (SLNB) with conventional intraoperative analysis is 8% false negative. One-step nucleic acid amplification (OSNA) is a molecular technique which allows real-time detection of mRNA encoding for cytokeratin 19. OSNA has been introduced in intraoperative analysis of several tumors to reduce false-negative rates and distinguish micrometastasis from macrometastasis. Our objective was to evaluate the impact of the introduction of OSNA in the intraoperative evaluation of the sentinel node (SN) in PTC. Design We analyzed a series of 35 patients subjected to SLNB. Methods All the dissected nodes, SN and non-SN, were evaluated with OSNA and cytology. Results We obtained a total of 110 SN. SLNB proved positive in 14 patients (40%) with cytology and in 23 (65.7%) with OSNA (P < 0.001). In the 29 patients with subsequent lymphadenectomy we obtained 360 lymph nodes ((52 positive in cytology (14.4%) and 107 in OSNA (29.7%)). Lymphadenectomy proved positive in 16 patients according to cytology (55%) and in 24 according to OSNA (83%) (P = 0002). The majority of patients with micrometastasis in SN showed only micrometastasis in lymphadenectomy. Conclusions The present study shows selective-sentinel-lymph-node-biopsy with one-step nucleic acid amplification technique to be feasible in papillary thyroid carcinoma. The quantitative nature of one-step nucleic acid amplification paves the way toward a more personalized surgical approach, limiting lymphadenectomy to patients with intraoperative evidence of macrometastasis in the sentinel node.


2020 ◽  
Vol 11 (SPL2) ◽  
pp. 220-227
Author(s):  
Nithin Diwagar K ◽  
Sridevi M ◽  
Chitra S

Galectin-3 is a beta-galactoside binding animal lectin, which is frequently associated with tumour progression and metastasis. In recent years, overexpression of Galectin-3 has been reported in various human cancers and more frequently in thyroid neoplasms. The aim of this study was to analyze the histomorphological characteristics of malignant thyroid neoplasms, subtype them according to the established classification system and to evaluate the expression of Galectin-3 immunostaining in papillary thyroid carcinoma. A total of 30 cases were included in the study, out of which 28 cases were papillary thyroid carcinoma and its variants and one case of medullary and anaplastic carcinoma. Majority of the papillary thyroid carcinoma cases were positive for Galectin 3 immunostaining (25/28 cases – 89%) in our study. We conclude that galectin-3 is consistently expressed in papillary carcinoma thyroid; however, there are few false-negative cases in this study and also other studies have reported Galectin 3 overexpression in non-papillary tumors. Hence, we cannot depend on Galectin 3 expression alone as a single diagnostic tool to detect papillary thyroid carcinoma.


Sign in / Sign up

Export Citation Format

Share Document